| Abatacept (Orencia) |
Active DM/PM/NM/JDM (over 18), overlap |
78 sites in US, Australia, S. America, Asia, Europe |
More details; BMS StudyConnect; NCT02971683 |
| Abatacept for treatment of myositis-associated interstitial lung disease (Attack My-ILD) |
ILD + antisynthetase antibody (Jo-1, PL-7, PL-12, EJ, OJ, KS) |
Los Angeles, CA, Denver, CO, Baltimore, MD, Boston, MA, Pittsburgh, PA |
More details; Courtney Ward 412-648-9989; NCT03215927 |
| Arimoclomol |
sIBM |
Kansas City, MO, London, UK +9 other sites expected |
More details; Laura Herbelin 913-588-5095; NCT02753530 |
| Belimumab |
Active DM/PM |
Sites in Long Island, NY, Phoenix, AZ, and UC Irvine, CA |
More details; Preeya Nandkumar; NCT02347891 |
| KZR-616 |
Active DM, PM |
10 sites in US |
More details; 650-822-5600; NCT04033926 |
| IVIg (Octagam 10%) |
DM |
27 sites worldwide |
More details; Mikaela Grupp 866-337-1868; NCT02728752 |
| Lenabasum |
Adults with DM |
12 sites in US, more expected |
More details; Lindsey Smith 1-617-963-0707; NCT03813160 |
| PF-06823859 |
DM |
12 sites in US |
More details; 1-800-718-1021; NCT03181893 |
| Rituximab vs Cyclophospahamide in Connective Tissue Disease-ILD (RECITAL) |
DM, PM, MCTD + ILD |
London, UK |
More details; Toby M Maher 02073518018; NCT01862926 |
| Sodium thiosulfate for treatment of calcinosis associated with juvenile and adult dermatomyositis |
DM and JDM with calcinosis |
National Institutes of Health, Bethesda, MD |
More details; Adam Schiffenbauer 301-451-6270; NCT03267277 |
| IgPro20 (Hizentra) |
Active DM, ADM (over 18) |
94 sites in US, Australia, Japan, Argentina, Mexico, Europe, Ukraine, Russia |
More details; Trial Registration Coordinator 610-878-4000; NCT04044690 |
| Tofacitinib (Xeljanz) |
Adults w DM w active, treatment resistant disease |
Johns Hopkins |
More details; Julie Paik, MD 410-550-1741; NCT03002649 |